Samchundang Secures $4 Billion European GLP-1 Deal with Breakthrough Patent-Circumventing Technology
核心洞察
Samchundang Pharmaceutical (搜索) signed an exclusive licensing agreement worth 5.3 trillion KRW ($4 billion) with a European pharmaceutical company for oral GLP-1 (搜索) generics across 11 European countries.
The company's proprietary SNAC-free formulation technology circumvents existing patents and achieves production costs at just 10% of selling price, enabling market entry years before competitors.
Samchundang will retain an unprecedented 60% of net sales profits in government tender markets, with the European semaglutide market projected to exceed 30 trillion KRW.
Samchundang Pharmaceutical (搜索) made headlines on February 26, 2026, when its stock price soared to record highs following the announcement of a landmark licensing agreement with a European pharmaceutical company. The South Korean drugmaker secured exclusive rights to commercialize its oral GLP-1 (搜索) generics—versions of diabetes drug Rybelsus and obesity treatment Wegovy—across 11 European countries for a total contract value of 5.3 trillion KRW (approximately $4 billion USD).
The agreement covers the United Kingdom, Belgium, Luxembourg, Finland, Greece, Ireland, Netherlands, Norway, Portugal, and Sweden, with Samchundang set to receive 30 million euros in upfront and milestone payments. Most remarkably, the company will retain 60% of net sales profits—a revenue-sharing structure that industry insiders describe as virtually unheard of in pharmaceutical licensing deals.
Market Impact and Stock Performance
The announcement triggered immediate investor enthusiasm, with Samchundang's stock climbing 22.13% to 712,000 KRW by 11:38 AM KRX time. By 1:34 PM, shares had surged to the daily upper limit of 757,000 KRW, representing a 29.85% increase. This meteoric rise propelled Samchundang to become the fourth-largest company by market capitalization on the KOSDAQ, overtaking Rainbow Robotics (搜索) and reaching a valuation of 17.7573 trillion KRW.
Breakthrough SNAC-Free Technology
The deal's exceptional terms stem from Samchundang's proprietary SNAC-free formulation technology, which eliminates the need for the SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) enhancer used in original GLP-1 (搜索) medications. This innovation allows the company to completely bypass existing formulation patents that would otherwise block generic competition.
"Our SNAC-free formulation perfectly circumvents the original patent, and the partner's audit confirmed our overwhelming cost competitiveness," a company representative explained. The technology achieves production costs at just 10% of the selling price, providing significant competitive advantages in price-sensitive European tender markets.
Strategic Market Positioning
The targeted European countries operate primarily on government tender systems, where competitive bidding and pricing play crucial roles in market access. A Samchundang official noted, "The countries involved in this contract operate on a government tender system. If patent circumvention and price competitiveness are secured, there's a high chance of expanding market share. Even in a tender-based structure, securing 60% of net profits is an exceptional condition."
While original substance patents for semaglutide expire around 2031, SNAC-based formulation patents remain in force for an additional five to six years. Samchundang's patent-circumventing technology positions the company to maintain market exclusivity during this critical window, potentially securing near-monopoly status in these countries.
Market Opportunity and Growth Projections
The European semaglutide market currently stands at approximately 9 trillion KRW, driven primarily by diabetes treatment applications, with annual growth rates of around 45%. Despite supply shortages and pending obesity treatment approvals in some countries, the market represents substantial opportunity.
"At the time of full-scale product launch, we expect the European semaglutide market to form a massive market exceeding 30 trillion KRW," the company projected. This optimistic outlook reflects both organic market growth and the potential expansion of obesity treatment indications across European markets.
Phased European Expansion Strategy
Samchundang has developed a methodical three-segment approach to European market entry: government tender markets, private insurance markets, and Eastern Europe. The current agreement secures the initial government tender segment, with ongoing negotiations for additional contracts in major EU markets including Germany, France, Italy, and Spain.
"We have secured the initial 11 countries and are now moving to finalize contracts with the remaining core EU markets," the company stated, indicating broader European ambitions beyond the current deal.
Financial Terms and Risk Management
The 10-year exclusive agreement includes automatic five-year renewals and incorporates risk-mitigating provisions. Should regulatory approvals not be obtained in specific countries, Samchundang faces no penalty or compensation obligations. This structure provides additional security while the company works with its European partner to navigate regulatory requirements across multiple jurisdictions.
The contract follows Samchundang's recent partnership with Japan's Daiichi Sankyo in January, further strengthening the company's global pharmaceutical credentials. As of December 2024, Samchundang reported total assets of 519.8 billion KRW, with annual sales of 210.9 billion KRW, positioning the European deal as a transformative opportunity for future profitability.
Global Pharmaceutical Implications
Industry observers view the agreement as setting new benchmarks for generics licensing, particularly regarding profit-sharing arrangements and patent circumvention strategies. The deal signals Samchundang's emergence as a significant player in the global pharmaceutical landscape, with management emphasizing continued expansion plans including North American market entry and oral insulin development projects.
"We will continue to prove our global milestones and enhance corporate value," the company stated, highlighting growing confidence in its S-PASS platform technology and broader strategic vision for international market dominance.